SCHEMBL806049

SCHEMBL806049

O=P(O)(CCP(=O)(O)c1ccccc1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 1.00
ALDH1A1 P00352 3/20 0.67
CA2 P00918 1/20 0.59
CA4 P22748 1/20 0.59
CA5A P35218 1/20 0.59
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
GAA P10253 2/20 0.54
MAPT P10636 1/20 0.50
ALPG P10696 1/20 0.50
ALOX12 P18054 1/20 0.50
NPY1R P25929 1/20 0.50
HTT P42858 1/20 0.50
NPY2R P49146 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
USP2 O75604 1/20 0.48
PTPN2 P17706 3/20 0.47
PTPN1 P18031 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14287997 0.90 CFTR (0.82) CFTRALDH1A1CA2CA4CA5A
SCHEMBL171269 0.88 CFTR (0.78) CFTRALDH1A1CA2CA4CA5A
SCHEMBL752882 0.88 CFTR (0.78) CFTRALDH1A1CA2CA4CA5A
Phosphine SCHEMBL27883782 0.86 CFTR (0.75) CFTRALDH1A1CA2CA4CA5A
SCHEMBL14809684 0.86 CFTR (0.75) CFTRALDH1A1CA2CA4CA5A
SCHEMBL14287993 0.86 CFTR (0.75) CFTRALDH1A1CA2CA4CA5A
SCHEMBL17488952 0.84 CFTR (0.72) CFTRALDH1A1CA2CA4CA5A
SCHEMBL65139 0.84 CFTR (0.72) CFTRALDH1A1CA2CA4CA5A
SCHEMBL19773247 0.84 CFTR (0.72) CFTRALDH1A1CA2CA4CA5A
SCHEMBL17488959 0.84 CFTR (0.72) CFTRALDH1A1CA2CA4CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10463639-B2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) 2019-11-05 US disclosed
US-10463639-B2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) 2019-11-05 US disclosed
US-10420738-B2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) 2019-09-24 US disclosed
US-10398665-B2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) 2019-09-03 US disclosed
US-10398665-B2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) 2019-09-03 US disclosed
EP-2816034-B1 COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION INST BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK (PL) 2018-12-12 EP disclosed
EP-2826771-B1 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction INST BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK (PL) 2018-12-12 EP disclosed
US-9826129-B2 Near-infrared-ray-absorbing composition, near-infrared-ray cut filter using same, manufacturing method therefor, camera module, and manufacturing method therefor FUJIFILM CORPORATION (JP) 2017-11-21 US disclosed
US-9826129-B2 Near-infrared-ray-absorbing composition, near-infrared-ray cut filter using same, manufacturing method therefor, camera module, and manufacturing method therefor FUJIFILM CORPORATION (JP) 2017-11-21 US disclosed
US-20160113896-A1 COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) 2016-04-28 US disclosed
EP-2616444-B1 COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION INST BIOCHEMII I BIOFIZYKI PAN (PL) 2015-08-26 EP disclosed
EP-2616444-B1 COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION INST BIOCHEMII I BIOFIZYKI PAN (PL) 2015-08-26 EP disclosed
EP-2826771-A2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction Instytut Biochemii I Biofizyki Polskiej Akademii Nauk (PL) 2015-01-21 EP disclosed
EP-2816035-A2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction Instytut Biochemii I Biofizyki Polskiej Akademii Nauk (PL) 2014-12-24 EP disclosed
EP-2816034-A2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction Instytut Biochemii I Biofizyki Polskiej Akademii Nauk (PL) 2014-12-24 EP disclosed
US-20130303761-A1 COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) 2013-11-14 US disclosed
US-20130303761-A1 COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) 2013-11-14 US disclosed
WO-2012036573-A2 COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION INSTYTUT BIOCHEMII I BIOFIZYKI PAN (PL) 2012-03-22 WO disclosed
EP-0006568-A1 Flame-retarding agents and their use in the preparation of fire-proof thermoplastic polymers HOECHST AKTIENGESELLSCHAFT (DE) 1980-01-09 EP disclosed
US-3962194-A FILAMENTS, FIBERS HOECHST AKTIENGESELLSCHAFT (DT) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10398665-B2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction CFTR, TMEM161A, TMEM120A CFTR 1/4885ALDH1A1 3701/4885CA2 2128/4885
US-10420738-B2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction CFTR, TMEM161A, TCOF1 CFTR 1/4885ALDH1A1 3883/4885CA2 2129/4885
US-20130303761-A1 COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION CFTR, TCOF1, ABCC2 CFTR 1/4885ALDH1A1 4338/4885CA2 2394/4885
US-20160113896-A1 COMPOUNDS AS MODULATORS OF A MUTANT CFTR PROTEIN AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH CFTR PROTEIN MALFUNCTION CFTR, TMEM161A, TCOF1 CFTR 1/4885ALDH1A1 3883/4885CA2 2129/4885
US-10463639-B2 Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction CFTR, TMEM161A, TCOF1 CFTR 1/4885ALDH1A1 3883/4885CA2 2129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.